Drug Trial Radar · NCT06693440
The Immune Assessment of PD-1 Antibody Therapy in Tumor
Last checked: Nov 20, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,000
Planned (sponsor's estimate)
Start
Jul 1, 2021
Primary completion
Nov 13, 2027
Study completion Nov 13, 2030
Sponsor
- Lead sponsor
- Quanli GaoGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Nov 18, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This retrospective study will leverage previous immune function monitoring results in conjunction with clinical case data at this medical center.
Conditions
- Efficacy, Team
- Adverse Event
Interventions
PD-1 InhibitorsDrug
Patients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: 6 months
- Adverse eventsTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.